Search
for
Sort by
Research 151–180 of 214
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Clinical characteristics, subtype classification, and prognostic factors of ophiasis: A retrospective study of 150 patients with therapeutic implications
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- British Association of Dermatologists living guideline for managing people with alopecia areata 2025
- Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
- Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- Alopecia areata and ritlecitinib: Unravelling response trajectories
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Autoinmune Alopecia/Alopecia Areata
- Deficiency in alopecia areata and responsiveness to vitamin D analogues: A prospective trial
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- Deficiency Pattern and Responsiveness in Clinical Settings in Discovering the Correlation between Vitamin D Analogues and Hair Growth in Alopecia Areata
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Alopecia Areata: An Updated Review for 2023
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Chitosan stimulates root hair callose deposition, endomembrane dynamics, and inhibits root hair growth